Nivalis Therapeutics,Inc. (NASDAQ:NVLS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS
On May15, 2017, Nivalis Therapeutics,Inc., a Delaware corporation
(the Company), held its Annual Meeting of stockholders. There
were 11,517,852 shares of common stock represented in person or
by valid proxies at the Meeting and entitled to be voted,
representing 73.6% of the 15,656,251 shares of common stock
outstanding as of the March22, 2017 record date. The stockholders
voted on two proposals at the Annual Meeting. The proposals are
described in detail in the Companys definitive proxy statement
filed with the Securities and Exchange Commission on April6,
2017. The following is a tabulation of the final voting results
for each of the proposals presented and voted on at the Annual
Meeting.
Proposal 1: The Companys stockholders elected two ClassII
Directors, each to serve for a three-year term expiring at the
2020 annual meeting of stockholders and until their respective
successors have been duly elected and qualified. The votes
regarding this proposal were as follows:
|
|
VotesFor |
|
Votes Withheld |
|
Broker Non-Votes |
|
|
|
Evan Loh, M.D. |
6,307,841 |
1,208,945 |
4,001,066 |
||||
|
Howard Furst, M.D. |
6,306,391 |
1,210,395 |
4,001,066 |
Proposal 2: The Companys stockholders ratified the
appointment of Ernst Young LLP as the Companys independent
registered public accounting firm for the year ending December31,
2017. The votes regarding this proposal were as follows:
|
VotesFor |
|
VotesAgainst |
|
Votes Abstained |
|
|
11,460,872 |
36,994 |
19,986 |
About Nivalis Therapeutics, Inc. (NASDAQ:NVLS)
Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR. Nivalis Therapeutics, Inc. (NASDAQ:NVLS) Recent Trading Information
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) closed its last trading session down -0.05 at 2.32 with 80,634 shares trading hands.